Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Yes Or No? Decisions Due On New EU Drug Applications

Executive Summary

Myovant, Bayer and Rhythm Pharmaceuticals are among the companies that could soon learn whether the European Medicines Agency thinks their drugs are fit for approval.

You may also be interested in...



Obesity Drug Imcivree Among Eight New Products To Win EMA Nod

The European Medicines Agency today revealed the names of the latest new products it believes should be approved for use across the EU.

Companies Brace For ‘Oral Explanations’ On EU Filings

Several companies may appear this week before the European Medicines Agency’s human medicines committee, the CHMP, to answer questions about their initial marketing authorization applications or indication extension requests.

EU Crunch Time For Bluebird’s Neurodegenerative Disorder Gene Therapy

The EU could become the first market in which eli-cel is approved if the gene therapy for cerebral adrenoleukodystrophy this week passes muster with the European Medicines Agency.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS144335

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel